TABLE 2.
The Gal status of PERV determines its sensitivity to NAb-mediated inactivationa
| Treatment | Titer of PER V-A as % of control (titer of control [IU/ml]) for producer cell line
|
|||||
|---|---|---|---|---|---|---|
| Gal-positive ST-IOWA+/+/PERV-A | Gal-null ST-IOWA−/−/PERV-A | Gal-null 293/PERV-A | Gal-positive ST-IOWA+/+/PERV-C | Gal-null ST-IOWA−/−/PERV-C | Gal-positive MPK | |
| FBS | 100 (170) | 100 (240) | 100 (170) | |||
| FBS + C′ | 135 | 79 | 100 | 100 (510) | 100 (890) | 100 (15) |
| NAb | 82 | 108 | 124 | |||
| NAb + C′ | 12 | 104 | 118 | 3 | 93 | 12 |
a
Relative titers of virus supernatants of PERV-A or PERV-C pseudotypes following treatment with 50 μg of NAb/ml and 12.5% rabbit serum (as a source of additional complement). Actual titers of the FBS-treated control are shown in parentheses. FBS, fetal bovine serum; C′, supplemental baby rabbit complement.